Document Detail

Anticoagulation for heart failure: selecting the best therapy.
MedLine Citation:
PMID:  19814664     Owner:  NLM     Status:  MEDLINE    
Heart failure (HF) incidence approaches 10 per 1000 population after the age of 65 years, and is the most common Medicare diagnosis. The management of HF patients has improved over the last decade, but the risk of thromboembolic complications is frequently underestimated and currently, no treatment options have been formally implemented to decrease the incidence of events. In particular, stroke is a major complication of HF. HF ranks second after atrial fibrillation in the number of cardiogenic strokes caused. The actual rate of stroke in recent HF trials ranges between 1.5 and 2.4% per year. Warfarin is of proven efficacy in patients with ischemic heart disease and atrial fibrillation, but there has been little research testing antithrombotic agents in patients with HF. Aspirin may be another promising drug, but trials have shown a higher rate of HF admissions with aspirin, suggesting that aspirin may attenuate the angiotensin-converting enzyme inhibitor effect on cardiac function. We eagerly await the completion of large, randomized trials to help guide us in these important issues affecting a large number of patients.
Shun Kohsaka; Shunichi Homma
Related Documents :
9591764 - Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated ...
3281264 - Clinical studies: evidence for intervention with specific antiplatelet drugs in arteria...
21035214 - Routine upstream versus selective downstream administration of glycoprotein iib/iiia in...
9739774 - Emergency management of acute myocardial infarction. focus on pharmacologic therapy.
2065414 - Perioperative stroke. part ii: cardiac surgery and cardiogenic embolic stroke.
22534054 - Comparison of usefulness of sokolow and cornell criteria for left ventricular hypertrop...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  7     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-09     Completed Date:  2010-01-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1209-17     Citation Subset:  IM    
Division of Cardiology, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, Japan 160-6562.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aneurysm / drug therapy
Anticoagulants / adverse effects,  pharmacology,  therapeutic use*
Atrial Fibrillation / complications,  drug therapy
Fibrinolytic Agents / adverse effects,  pharmacology,  therapeutic use*
Heart Failure / complications,  drug therapy*
Thromboembolism / complications,  drug therapy
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy of aspirin for secondary prevention in patients with peripheral artery disease.
Next Document:  Statin use before and after acute ischemic stroke onset improves neurological outcome.